Monte Rosa Therapeutics, Inc. (GLUE): Total Liabilities
$215.60M
As of 2025-12-31
$203.88M
As of 2026-06-30
+44.8%
3-year compound annual growth
+48.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $215.60M | -0.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $215.80M | +73.3% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $124.50M | +75.4% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $70.98M | +277.3% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $18.81M | -38.0% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $30.34M | n/a | 2022-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $611.11M | -7.6% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
Compare GLUE, ATRA, IBRX, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗